These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9815945)

  • 1. p53 antibodies in patients with various types of cancer: assay, identification, and characterization.
    Lubin R; Schlichtholz B; Teillaud JL; Garay E; Bussel A; Wild CP
    Clin Cancer Res; 1995 Dec; 1(12):1463-9. PubMed ID: 9815945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of serum anti-p53 antibodies in patients with various types of cancer].
    Sakai H
    Rinsho Byori; 2002 Jan; 50(1):90-2. PubMed ID: 11871143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot.
    Schlichtholz B; Legros Y; Gillet D; Gaillard C; Marty M; Lane D; Calvo F; Soussi T
    Cancer Res; 1992 Nov; 52(22):6380-4. PubMed ID: 1423285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
    Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T
    Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 Antibodies in the sera of patients with various types of cancer: a review.
    Soussi T
    Cancer Res; 2000 Apr; 60(7):1777-88. PubMed ID: 10766157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [P53 antibodies: a new method for the analysis of alterations of the p53 gene: application to breast cancer].
    Soussi T; Peyrat JP; Lubin R; Bonneterre J
    Pathol Biol (Paris); 1996 Apr; 44(4):232-4. PubMed ID: 8763583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
    Looi K; Megliorino R; Shi FD; Peng XX; Chen Y; Zhang JY
    Oncol Rep; 2006 Nov; 16(5):1105-10. PubMed ID: 17016600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
    Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
    Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-P53 antibodies in Brazilian brain tumor patients.
    Fonseca RF; Kawamura MT; Oliveira JA; Teixeira A; Alves G; Carvalho Mda G
    Genet Mol Res; 2003 Jun; 2(2):185-90. PubMed ID: 14966683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas.
    Forslund A; Kressner U; Lindmark G; Inganäs M; Lundholm K
    Int J Oncol; 2001 Sep; 19(3):501-6. PubMed ID: 11494027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical importance of serum anti-p53 antibodies as tumor markers].
    Sakai H; Okamoto E
    Rinsho Byori; 2002 Oct; 50(10):970-5. PubMed ID: 12451677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the anti-p53 antibody response in cancer patients.
    Labrecque S; Naor N; Thomson D; Matlashewski G
    Cancer Res; 1993 Aug; 53(15):3468-71. PubMed ID: 8339249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of p53 gene change and serum antibody level in phase II clinical trial of ad p53 gene therapy].
    Zhao M; Xiao SW; Yang JX; Zhang SW; Lü YY
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3495-8. PubMed ID: 16686067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral p53 antibody response is a prognostic parameter in ovarian cancer.
    Mayerhofer K; Tempfer C; Kucera E; Hefler L; Zeisler H; Kainz C; Zeillinger R; Sliutz G
    Anticancer Res; 1999; 19(1B):875-8. PubMed ID: 10216509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection.
    Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY
    Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors.
    von Brevern MC; Hollstein MC; Cawley HM; De Benedetti VM; Bennett WP; Liang L; He AG; Zhu SM; Tursz T; Janin N; Trivers GE
    Cancer Res; 1996 Nov; 56(21):4917-21. PubMed ID: 8895744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of p53 autoantibodies in sera from glioma patients.
    Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
    Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The detection of quantitative serum p53 protein in lung cancer.
    Sen E; Gönüllü U; Akar N
    Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.
    Shimada H; Ochiai T; Nomura F;
    Cancer; 2003 Feb; 97(3):682-9. PubMed ID: 12548611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.
    Müller M; Meyer M; Schilling T; Ulsperger E; Lehnert T; Zentgraf H; Stremmel W; Volkmann M; Galle PR
    Int J Oncol; 2006 Oct; 29(4):973-80. PubMed ID: 16964393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.